Delcath Systems Inc
DCTH
DCTH: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
moreShow DCTH Financials
Recent trades of DCTH by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Roger W. Marshall House / R | Sale $1,001 - $15,000 | Jun. 09, 2017 |
Recently reported changes by institutional investors
Quarterly net insider trading by DCTH's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Apparatus for removing chemotherapy compounds from blood Apr. 25, 2023
-
Patent Title: Apparatus for removing chemotherapy compounds from blood Feb. 08, 2022
-
Patent Title: Filter and frame apparatus and method of use Aug. 10, 2021
-
Patent Title: Apparatus for removing chemotherapy compounds from blood Feb. 25, 2020
-
Patent Title: Apparatus for removing chemotherapy compounds from blood Aug. 06, 2019
-
Patent Title: Filter and frame apparatus and method of use Feb. 05, 2019
-
Patent Title: Apparatus for removing chemotherapy compounds from blood Oct. 16, 2018
-
Patent Title: Apparatus for removing chemotherapy compounds from blood Jul. 18, 2017
-
Patent Title: Method of selecting chemotherapeutic agents for an isolated organ or regional therapy Jan. 10, 2017
-
Patent Title: Filter and frame apparatus and method of use Apr. 19, 2016
-
Patent Title: Dual filter Jul. 08, 2014
Federal grants, loans, and purchases
Followers on DCTH's company Twitter account
Number of mentions of DCTH in WallStreetBets Daily Discussion
Recent insights relating to DCTH
Recent picks made for DCTH stock on CNBC
ETFs with the largest estimated holdings in DCTH
Flights by private jets registered to DCTH